Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adobe Systems Inc (ADBE) vs Biogen Inc (BIIB) Price & Performance

Adobe Systems IncTrade
Biogen IncTrade

Price performance (Past 24H)

Key statistics

Adobe Systems Inc vs Biogen Inc — how do they compare? Adobe Systems Inc trades at $256.76 (market cap $104.82B), while Biogen Inc trades at $205 (market cap $30.13B). The key difference: Adobe Systems Inc is far larger — about 3.5× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.

ADBEBIIB
Market Cap
$104.82B$30.13B
Volume
5,187,646
Sector
TechnologyHealth
52-Week High
$367.46$216.63
52-Week Low
$193.41$128.93
Enterprise Value
$106.26B$37.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adobe Systems Inc

Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability margins. Recent earnings beats and accelerating revenue growth contrast with market concerns about AI competition and CEO transition.

Adobe presents a compelling value opportunity trading below analyst consensus targets despite strong operational performance. Key risks include AI disruption threats and ongoing leadership transition, while institutional accumulation and positive earnings momentum support potential upside. The stock's current valuation multiples appear attractive relative to growth prospects.

Biogen Inc

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

Returns comparison

Trailing returns across standard periods

About Adobe Systems Inc

Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.

Read more on ADBE

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB